| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2009
|
2.32
|
|
2
|
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
|
J Clin Oncol
|
2003
|
2.30
|
|
3
|
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.
|
Clin Cancer Res
|
2005
|
2.22
|
|
4
|
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
|
J Clin Oncol
|
2011
|
1.80
|
|
5
|
Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer.
|
Gynecol Oncol
|
2007
|
1.61
|
|
6
|
Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study.
|
Cancer Res
|
2003
|
1.37
|
|
7
|
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2007
|
1.31
|
|
8
|
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2011
|
1.23
|
|
9
|
Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2006
|
1.15
|
|
10
|
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2009
|
1.14
|
|
11
|
Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2009
|
1.09
|
|
12
|
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2011
|
1.08
|
|
13
|
Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2006
|
1.04
|
|
14
|
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study.
|
Gynecol Oncol
|
2010
|
1.04
|
|
15
|
Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
|
J Clin Oncol
|
2008
|
1.01
|
|
16
|
Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
|
J Clin Oncol
|
2008
|
0.98
|
|
17
|
Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2008
|
0.98
|
|
18
|
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
|
Gynecol Oncol
|
2011
|
0.95
|
|
19
|
A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
|
Gynecol Oncol
|
2007
|
0.94
|
|
20
|
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2009
|
0.93
|
|
21
|
Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.
|
Int J Cancer
|
2009
|
0.93
|
|
22
|
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2007
|
0.92
|
|
23
|
Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study.
|
Gynecol Oncol
|
2009
|
0.92
|
|
24
|
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.
|
Gynecol Oncol
|
2010
|
0.92
|
|
25
|
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
|
Gynecol Oncol
|
2010
|
0.91
|
|
26
|
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2013
|
0.90
|
|
27
|
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2011
|
0.89
|
|
28
|
Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer.
|
J Proteome Res
|
2012
|
0.88
|
|
29
|
The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study.
|
Gynecol Oncol
|
2011
|
0.87
|
|
30
|
Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
|
Gynecol Oncol
|
2012
|
0.86
|
|
31
|
Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study.
|
Cancer
|
2004
|
0.85
|
|
32
|
A GOG 210 aCGH study of gain at 1q23 in endometrioid endometrial cancer in the context of racial disparity and outcome.
|
Genes Chromosomes Cancer
|
2010
|
0.84
|
|
33
|
Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2012
|
0.83
|
|
34
|
Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial.
|
Gynecol Oncol
|
2011
|
0.83
|
|
35
|
Gene expression analysis of early stage endometrial cancers reveals unique transcripts associated with grade and histology but not depth of invasion.
|
Front Oncol
|
2013
|
0.83
|
|
36
|
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2012
|
0.81
|
|
37
|
Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: a gynecologic oncology group study.
|
Gynecol Oncol
|
2011
|
0.80
|
|
38
|
Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study.
|
Gynecol Oncol
|
2012
|
0.80
|
|
39
|
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.
|
Gynecol Oncol
|
2008
|
0.80
|
|
40
|
Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study.
|
Br J Clin Pharmacol
|
2006
|
0.80
|
|
41
|
Smoking behavior in women with locally advanced cervical carcinoma: a Gynecologic Oncology Group study.
|
Am J Obstet Gynecol
|
2009
|
0.79
|
|
42
|
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2005
|
0.79
|
|
43
|
Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2009
|
0.78
|
|
44
|
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
|
Gynecol Oncol
|
2006
|
0.77
|
|
45
|
A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study.
|
Cancer Causes Control
|
2012
|
0.77
|
|
46
|
Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study.
|
Front Oncol
|
2013
|
0.75
|
|
47
|
Relative Effects of Age, Race, and Stage on Mortality in Gestational Choriocarcinoma.
|
Int J Gynecol Cancer
|
2017
|
0.75
|
|
48
|
Transcript expression in endometrial cancers from Black and White patients.
|
Gynecol Oncol
|
2013
|
0.75
|